Extra-pancreatic effects of incretin-based therapies. - Wikidata - wikimedia - TriplyDB

Extra-pancreatic effects of incretin-based therapies.

Extra-pancreatic effects of incretin-based therapies.

http://www.wikidata.org/entity/Q38194069

about

Advances in the treatment of type 2 diabetes: impact of dulaglutide Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties Gastrointestinal hormones and polycystic ovary syndrome.Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes.Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.GLP-1(28-36)amide, a Long Ignored Peptide Revisited.

P2860

Q26746220-BDCDAF37-F411-455F-B704-A84FE233BF20 Q36516919-8DFD6681-7FEE-45BC-B821-9EE7B32F49AF Q37720797-AA6B5D69-0E93-4AF1-BDBF-67A4C7D0B481 Q38208929-3EFC301A-5420-4B22-9582-2D02ABBA1B58 Q38242089-4301B4CE-24DE-4EBF-954C-6FFA220069A0 Q38371242-EE2ABE7E-7265-425F-A4FC-D33C6E07CE5E Q38649250-DED7BA9B-7B70-4422-A974-A2237A0F4AF6 Q38758454-191A8A38-90FD-46A7-A6B4-4DC222DFE2BC Q41965223-C936D981-4CBA-4349-960B-AB519BB40910 Q42145401-2238AE65-8474-4739-B637-B52CC2C7062A Q42876331-EE31195A-F778-4841-AEF6-5B3D1FDA7AF5 Q43105364-566C35D4-BDE8-4470-9B3F-C0058EDE8CE6

P2860

Extra-pancreatic effects of incretin-based therapies.

http://www.wikidata.org/entity/Q38194069

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Extra-pancreatic effects of incretin-based therapies.

@en

type

label

Extra-pancreatic effects of incretin-based therapies.

@en

prefLabel

Extra-pancreatic effects of incretin-based therapies.

@en

P1433

Q38194069-5CC411BC-EFC8-4680-8D48-894A01F906CC

P1476

Q38194069-9D13B523-2B5A-448C-B04A-D7CBE4FCB71B

P2093

Q38194069-F99D6886-93C6-4099-BE35-D5AEC791D15C

P2860

Q38194069-068A7CD5-16C4-4AC8-8CF6-C5BB914D1C46

Q38194069-07D192F5-08E7-4B3E-B5C1-ADAE10233F44

Q38194069-0A67DAC0-1EC9-479A-9BDF-2700639014EC

Q38194069-10E13F4E-8305-492D-9742-78BE1840AA40

Q38194069-11769A73-9016-495D-B05E-23E220B99FB2

Q38194069-13611F27-E19B-4467-94CE-8BF74E2B0AC4

Q38194069-151B8087-B062-47AF-AAA5-74CED949ACE6

Q38194069-16CDF8D6-94E5-4382-9AF4-551DB4245A7B

Q38194069-1D29578A-CF15-4E7D-9C0F-7C4A56D00C40

Q38194069-20194EAB-2263-43EE-B493-5A820E1DE3B9

P2888

Q38194069-DB27D657-DB9E-4176-A21F-28A4949950F1

P304

Q38194069-386BB215-5A0C-455D-AACC-379109E7201C

P31

Q38194069-A4ABE149-EAD6-4CE8-B433-8D15FABD0BF3

P356

Q38194069-AE4C9310-22B8-4B8A-AA80-F03FCA35EABE

P433

Q38194069-16302DCA-B793-4629-96AC-4986ABB7E7AE

P478

Q38194069-343E0E3B-62D2-4F7A-B701-F82127950850

P577

Q38194069-E2511A2C-EF1A-4580-98D9-3DD31C82E9C6

P5875

Q38194069-217DEA9D-BCDF-4568-8F58-322F515D2585

P698

Q38194069-663878BD-8E1C-4AE1-A911-1BBB7A4E1D38

P356

S12020-014-0223-0

P1433

P1476

Extra-pancreatic effects of incretin-based therapies.

@en

P2093

Baptist Gallwitz

http://www.w3.org/2001/XMLSchema#string

P2860

A role for glucagon-like peptide-1 in the central regulation of feeding

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

The Physiology of Glucagon-like Peptide 1

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

Effects of intensive glucose lowering in type 2 diabetes

P2888

s12020-014-0223-0

P304

360-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-014-0223-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260611153

http://www.w3.org/2001/XMLSchema#string

P698

24604239

http://www.w3.org/2001/XMLSchema#string